Multidrug Resistant Acinetobacter baumannii: Resistance by Any Other Name Would Still be Hard to Treat
2019
Purpose of Review
Acinetobacter baumannii (AB) is an infamous nosocomial pathogen with a seemingly limitless capacity for antimicrobial resistance, leading to few treatment options and poor clinical outcomes. The debatably low pathogenicity and virulence of AB are juxtaposed by its exceptionally high rate of infection-related mortality, likely due to delays in time to effective antimicrobial therapy secondary to its predilection for resistance to first-line agents. Recent studies of AB and its infections have led to a burgeoning understanding of this critical microbial threat and provided clinicians with new ammunition for which to target this elusive pathogen. This review will provide an update on the virulence, resistance, diagnosis, and treatment of multidrug resistant (MDR) AB.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
133
References
19
Citations
NaN
KQI